医学
重症监护室
肺炎
内科学
随机对照试验
临床终点
不利影响
倾向得分匹配
临床试验
机械通风
作者
Lucrezia Spadera,Marina Lugarà,Maria Spadera,Mariano Conticelli,Gabriella Oliva,V. Bassi,Valentina Apuzzi,Francesco Calderaro,Olimpia Fattoruso,Pietro Hiram Guzzi,Maurizio D’Amora,Oriana Catapano,Roberta Marra,Maria Galdo,Michele Zappalà,Tomoyuki Inui,Martin Mette,Giuseppe Vitiello,Miriam Corvino,Giuseppe Tortoriello
标识
DOI:10.1016/j.biopha.2023.115894
摘要
Based on a growing body of evidence that a dysregulated innate immune response mediated by monocytes/macrophages plays a key role in the pathogenesis of COVID-19, a clinical trial was conducted to investigate the therapeutic potential and safety of oral macrophage activating factor (MAF) plus standard of care (SoC) in the treatment of hospitalized patients with COVID-19 pneumonia. Ninety-seven hospitalized patients with confirmed COVID-19 pneumonia were treated with oral MAF and a vitamin D3 supplement, in combination with SoC, in a single-arm, open label, multicentre, phase II clinical trial. The primary outcome measure was a reduction in an intensive care unit transfer rate below 13% after MAF administration. At the end of the study, an additional propensity score matching (PSM) analysis was performed to compare the MAF group with a control group treated with SoC alone. Out of 97 patients treated with MAF, none needed care in the ICU and/or intubation with mechanical ventilation or died during hospitalization. Oxygen therapy was discontinued after a median of nine days of MAF treatment. The median length of viral shedding and hospital stay was 14 days and 18 days, respectively. After PSM, statistically significant differences were found in all of the in-hospital outcomes between the two groups. No mild to serious adverse events were recorded during the study. Notwithstanding the limitations of a single-arm study, which prevented definitive conclusions, a 21-day course of MAF treatment plus SoC was found to be safe and promising in the treatment of hospitalized adult patients with COVID-19 pneumonia. Further research will be needed to confirm these preliminary findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI